Skip to content

Alnylam Pharmaceuticals Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 29, 2026 results vs estimates

Alnylam Pharmaceuticals Inc · E.ALNY.NASDAQ · United States
Use symbol E.ALNY.NASDAQ in our API & Excel add-in to retrieve this data ↓
174.00
(-0.25%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum -100%
Trend -100%
Bubble Risk LOW
Realised Volatility (20D) 95.66%

Alnylam Pharmaceuticals Inc Forecast

Alnylam Pharmaceuticals Inc short-term momentum is strongly negative (up over 0 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is strongly negative (0 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 95.7% a year, a typical one-standard-deviation range is 150.56–197.44 over a week, 125.95–222.05 over a month and 7.5586–340.44 over a year. (Signals as of 1 Nov 2026.)

Alnylam Pharmaceuticals Inc Price Chart

MacroFinance.ai

Alnylam Pharmaceuticals Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Alnylam Pharmaceuticals Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Alnylam Pharmaceuticals Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Alnylam Pharmaceuticals Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Alnylam Pharmaceuticals Inc
P/E
8.82x
Cheap vs own history
QoQ −78.2%
YoY −99.4%
now 8.81687.29 low1,444 high
ⓘP/E As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Alnylam Pharmaceuticals Inc
P/S
4.79x
Cheap vs own history
QoQ −29.5%
YoY −74.3%
now 4.79113.96 low19.6 high
ⓘP/S As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Alnylam Pharmaceuticals Inc
P/B
6.66x
Cheap vs own history
QoQ −72.4%
YoY −97.4%
now 6.66485.51 low269.02 high
ⓘP/B As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Alnylam Pharmaceuticals Inc
EV/EBITDA
17.38x
Cheap vs own history
QoQ −34.7%
YoY −94.5%
now 17.3814.04 low329.55 high
ⓘEV/EBITDA As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Alnylam Pharmaceuticals Inc
EV/Sales
4.33x
Cheap vs own history
QoQ −32.1%
YoY −76.3%
now 4.32733.5 low19.16 high
ⓘEV/Sales As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Alnylam Pharmaceuticals Inc
FCF Yield
2.1%
Strong vs own history
QoQ +25.5%
YoY +464.4%
now 2.08470.35 low2.52 high
ⓘFCF Yield As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Alnylam Pharmaceuticals Inc
Earnings Yield
11.3%
Strong vs own history
QoQ +358.4%
YoY +15,504.1%
now 11.3420.07 low13.72 high
ⓘEarnings Yield As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Alnylam Pharmaceuticals Inc
Market Cap
$24.0B
Mid-range vs own history
QoQ −26.5%
YoY −59.9%
now 24018.9619,853 low62,922 high
ⓘMarket Cap As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Alnylam Pharmaceuticals Inc
Net Debt
-$2.3B
Low vs own history
QoQ +13.9%
YoY +64.2%
now -2325.262-2,325 low-1,416 high
ⓘNet Debt As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Alnylam Pharmaceuticals Inc
Net Debt / EBITDA
-1.86x
Mid-range vs own history
QoQ +5.0%
YoY −75.4%
now -1.8629-7.59 low-1.77 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Alnylam Pharmaceuticals Inc
Current Ratio
2.48x
Weak vs own history
QoQ −18.9%
YoY −2.5%
now 2.47832.48 low3.13 high
ⓘCurrent Ratio As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Alnylam Pharmaceuticals Inc
Quick Ratio
2.43x
Weak vs own history
QoQ −18.8%
YoY −2.6%
now 2.42692.43 low3.06 high
ⓘQuick Ratio As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Alnylam Pharmaceuticals Inc
Interest Coverage
3.27x
Strong vs own history
QoQ −3.1%
YoY +306.8%
now 3.26740.8 low3.37 high
ⓘInterest Coverage As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Alnylam Pharmaceuticals Inc
Debt / Equity
0.35x
Low vs own history
QoQ −62.6%
YoY −93.7%
now 0.35020.35 low5.59 high
ⓘDebt / Equity As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Alnylam Pharmaceuticals Inc
Piotroski F-Score
5
Mid-range vs own history
QoQ −16.7%
YoY −16.7%
now 55 low7 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Alnylam Pharmaceuticals Inc
Altman Z-Score
4.13
Mid-range vs own history
QoQ −21.4%
YoY −41.5%
now 4.133.56 low7.45 high
ⓘAltman Z-Score As of 22 Nov 2026.See Alnylam Pharmaceuticals Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  20 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Alnylam Pharmaceuticals Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Alnylam Pharmaceuticals Inc fundamentals: income statement, balance sheet & cash flow

Alnylam Pharmaceuticals Inc reported revenue of $3.71bn and net income of $313.7m in FY2025, the year ended 31 December 2025 — revenue up 65.2% and net income up 212.8% on the prior year. Free cash flow was $465.4m. These figures are as reported in the filings, not restated: 24 fiscal years and 95 quarters of history, back to December 2002. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$3.71bn
+65.2%
Net income
$313.7m
+212.8%
Gross margin
81.77%
Free cash flow
$465.4m
+1,192.7%
Net debt
-$378.9m
Shares short (30 Oct 2026)
5.47m
1.91 days to cover
Alnylam Pharmaceuticals Inc income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue3,713.92,248.21,828.31,037.4844.3
Cost of revenue677.2323.4310.4168.8140.1
Gross profit3,036.81,924.91,517.9868.6704.1
Research & development1,324.51,126.21,004.4883.0792.2
Selling, general & admin.1,210.7975.5795.6770.7620.6
Operating income501.6-176.9-282.2-785.1-708.7
EBITDA631.4-178.8-258.2-926.6-661.6
Interest expense252.6141.9121.2156.0143.0
Pre-tax income323.2-377.4-433.5-1,127.0-852.1
Income tax9.4-99.26.74.20.7
Net income313.7-278.2-440.2-1,131.2-852.8

Download Alnylam Pharmaceuticals Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ALNY.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 24 fiscal years and 95 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Alnylam Pharmaceuticals Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Alnylam Pharmaceuticals Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Alnylam Pharmaceuticals Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Alnylam Pharmaceuticals Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Alnylam Pharmaceuticals Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Alnylam Pharmaceuticals Inc (United States)

Alnylam Pharmaceuticals Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Alnylam Pharmaceuticals Inc?
Alnylam Pharmaceuticals Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Alnylam Pharmaceuticals Inc price?
The latest close is 174 (1 Nov 2026), -0.25% on the day. The price at the top of the page refreshes during the trading day.
Is Alnylam Pharmaceuticals Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly negative (0 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly negative (0 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Alnylam Pharmaceuticals Inc?
20-day realised volatility is 95.7% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 27.6% over a month and 13.5% over a week.
What factors affect Alnylam Pharmaceuticals Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Alnylam Pharmaceuticals Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Alnylam Pharmaceuticals Inc?
58 backtested tactical asset allocation strategies trade Alnylam Pharmaceuticals Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Alnylam Pharmaceuticals Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Alnylam Pharmaceuticals Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Alnylam Pharmaceuticals Inc historical data?
In the Free historical data section of this page: the last 10 years of Alnylam Pharmaceuticals Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Alnylam Pharmaceuticals Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Alnylam Pharmaceuticals Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ALNY.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20143.82
2026-11-19147.82
2026-11-18149.4
2026-11-17156.5
2026-11-16159.73
2026-11-13165.04
2026-11-12156.65
2026-11-11159.85
2026-11-10151.64
2026-11-09156.61
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.